152 related articles for article (PubMed ID: 35377946)
1. The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
Sihag S; Nussenzweig SC; Walch HS; Hsu M; Tan KS; De La Torre S; Janjigian YY; Maron SB; Ku GY; Tang LH; Shah PM; Wu A; Jones DR; Solit DB; Schultz N; Ganesh K; Berger MF; Molena D
Clin Cancer Res; 2022 Jun; 28(12):2669-2678. PubMed ID: 35377946
[TBL] [Abstract][Full Text] [Related]
2. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
[TBL] [Abstract][Full Text] [Related]
3. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool?
Nason KS
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2286-7. PubMed ID: 25444198
[No Abstract] [Full Text] [Related]
4. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
[TBL] [Abstract][Full Text] [Related]
5. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
6. Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.
Obulkasim A; Ylstra B; van Essen HF; Benner C; Stenning S; Langley R; Allum W; Cunningham D; Inam I; Hewitt LC; West NP; Meijer GA; van de Wiel MA; Grabsch HI
Oncotarget; 2016 Jul; 7(28):44084-44095. PubMed ID: 27286451
[TBL] [Abstract][Full Text] [Related]
7. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
8. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy.
Plum PS; Löser H; Zander T; Essakly A; Bruns CJ; Hillmer AM; Alakus H; Schröder W; Büttner R; Gebauer F; Quaas A
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1031-1040. PubMed ID: 33300112
[TBL] [Abstract][Full Text] [Related]
9. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
11. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
[TBL] [Abstract][Full Text] [Related]
13. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
15. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.
Murugaesu N; Wilson GA; Birkbak NJ; Watkins T; McGranahan N; Kumar S; Abbassi-Ghadi N; Salm M; Mitter R; Horswell S; Rowan A; Phillimore B; Biggs J; Begum S; Matthews N; Hochhauser D; Hanna GB; Swanton C
Cancer Discov; 2015 Aug; 5(8):821-831. PubMed ID: 26003801
[TBL] [Abstract][Full Text] [Related]
16. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
Aichler M; Motschmann M; Jütting U; Luber B; Becker K; Ott K; Lordick F; Langer R; Feith M; Siewert JR; Walch A
Oncotarget; 2014 Aug; 5(16):6620-32. PubMed ID: 25216514
[TBL] [Abstract][Full Text] [Related]
19. Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction.
Li S; Li B; Wang J; Zhang D; Liu Z; Zhang Z; Zhang W; Wang Y; Bai D; Guan J; Zhang Y
Oncol Res; 2017 Jan; 25(1):93-97. PubMed ID: 28081737
[TBL] [Abstract][Full Text] [Related]
20. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
